Onconova’s narazacicilib differentiating itself in MCL, says H.C. Wainwright

H.C. Wainwright tells investors in a research note that Onconova’s CDK 4/6 inhibitor, narazaciclib, continues to differentiate itself and carve an “exciting” path in mantle cell lymphoma lines. The firm, which made no change to its Buy rating or $11 price target, says the continued stream of positive data in relation to narazaciclib is “quite encouraging,” in MCL, as ibrutinib represents the current standard-of-care for MCL patients.